A Review of Switching Strategies for Patients with Schizophrenia Comorbid with Metabolic Syndrome or Metabolic Abnormalities

References

• Bosia M, Pigoni A, Cavallaro R. Genomics and epigenomics in novel schizophrenia drug discovery: translating animal models to clinical research and back. Expert Opin Drug Discov. 2015;10(2):125–139. doi:10.1517/17460441.2015.97655225345474
   PubMed Web of Science ®Google Scholar
• The IDF consensus worldwide definition of the metabolic syndrome. Available from: http://www.idf.org/webdata/docs/IDF_Metasyndrome_definition.pdf. Accessed 1124, 2020.
   Google Scholar
• Malhotra N, Grover S, Chakrabarti S, Kulhara P. Metabolic syndrome in schizophrenia. Indian J Psychol Med. 2013;35(3):227–240. doi:10.4103/0253-7176.11947124249923
   PubMedGoogle Scholar
• Diabetes Branch of Chinese Medical Association. Guidelines for prevention and treatment of type 2 diabetes in China (2017 edition). Chin J Pract Int Med. 2018;38(4):292–344. doi:10.19538/j.nk2018040108
   Google Scholar
• De Hert M, Schreurs V, Vancampfort D, Van Winkel R. Metabolic syndrome in people with schizophrenia: a review. World Psychiatry. 2009;8(1):15–22. doi:10.1002/j.2051-5545.2009.tb00199.x19293950
   PubMed Web of Science ®Google Scholar
• De Hert MA, van Winkel R, Van Eyck D, et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res. 2006;83(1):87–93. doi:10.1016/j.schres.2005.12.85516481149
   PubMed Web of Science ®Google Scholar
• De Hert M, van Winkel R, Van Eyck D, et al. Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clin Pract Epidemiol Ment Health. 2006;2:14. doi:10.1186/1745-0179-2-1416803620
   PubMedGoogle Scholar
• Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, Yu W, De Hert M. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders–a systematic review and meta-analysis. Schizophr Bull. 2013;39(2):306–318. doi:10.1093/schbul/sbr14822207632
   PubMed Web of Science ®Google Scholar
• Vancampfort D, Stubbs B, Mitchell AJ, et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry. 2015;14(3):339–347. doi:10.1002/wps.2025226407790
   PubMed Web of Science ®Google Scholar
• Lee JS, Kwon JS, Kim D, et al. Prevalence of metabolic syndrome in patients with schizophrenia in Korea: a Multicenter Nationwide Cross-Sectional Study. Psychiatry Investig. 2017;14(1):44–50. doi:10.4306/pi.2017.14.1.44
   PubMed Web of Science ®Google Scholar
• Schorr SG, Slooff CJ, Bruggeman R, Taxis K. The incidence of metabolic syndrome and its reversal in a cohort of schizophrenic patients followed for one year. J Psychiatr Res. 2009;43(13):1106–1111. doi:10.1016/j.jpsychires.2009.03.00219398113
   PubMed Web of Science ®Google Scholar
• McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80(1):19–32. doi:10.1016/j.schres.2005.07.01416137860
   PubMed Web of Science ®Google Scholar
• Sugawara N, Yasui-Furukori N, Sato Y, et al. Prevalence of metabolic syndrome among patients with schizophrenia in Japan. Schizophr Res. 2010;123(2–3):244–250. doi:10.1016/j.schres.2010.08.03020850274
   PubMed Web of Science ®Google Scholar
• Srisurapanont M, Likhitsathian S, Boonyanaruthee V, Charnsilp C, Jarusuraisin N. Metabolic syndrome in Thai schizophrenic patients: a naturalistic one-year follow-up study. BMC Psychiatry. 2007;7:14. doi:10.1186/1471-244X-7-1417448257
   PubMed Web of Science ®Google Scholar
• Wenlong S, Chenhu L, Shunzeng R, Guilai Z, Hong Z. Investigation on the prevalence of metabolic syndrome in patients with schizophrenia. Neurol Dis Mental Health. 2007;7(6):431–433. doi:10.3969/j.issn.1009-6574.2007.06.007
   Google Scholar
• Dehua Y, Lihua L, Yong F, Yuxia D. Investigation of schizophrenia patients with metabolic syndrome. J Clin Psychiatry. 2011;21(5):326–328.
   Google Scholar
• Jie Y, Haijun L, Yazhong L, Jianhua M, Zhimeng L. The prevalence of metabolic syndrome and related factors in patients with schizophrenia. Chin J Health Psychol. 2012;20(6):808–809.
   Google Scholar
• Jiqun X, Weilu Y, Shaowei O, Yuanhui Z, Zhibin Z. Investigation and analysis of the incidence of metabolic syndrome and related risk factors in outpatients with schizophrenia. China Contemp Med. 2018;25(24):56–58. doi:10.3969/j.issn.1674-4721.2018.24.016
   Google Scholar
• Yan L, Huafang L, Yumei J, Peiqing W, Zhushu Q. The prevalence and related factors of metabolic syndrome in hospitalized patients with schizophrenia. Shanghai Psychiatry. 2009;21(1):16–19. doi:10.3969/j.issn.1002-0829.2009.01.004
   Google Scholar
• Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010;56(14):1113–1132. doi:10.1016/j.jacc.2010.05.03420863953
   PubMed Web of Science ®Google Scholar
• Kritharides L, Chow V, Lambert TJ. Cardiovascular disease in patients with schizophrenia. Med J Aust. 2017;206(2):91–95. doi:10.5694/mja16.0065028152356
   PubMed Web of Science ®Google Scholar
• Hayes JF, Marston L, Walters K, King MB, Osborn D. Mortality gap for people with bipolar disorder and schizophrenia: UK-based cohort study 2000–2014. Br J Psychiatry. 2017;211(3):175–181. doi:10.1192/bjp.bp.117.20260628684403
   PubMed Web of Science ®Google Scholar
• Arango C, Bobes J, Aranda P, Carmena R, Garcia-Garcia M, Rejas J. A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: findings from the CLAMORS study. Schizophr Res. 2008;104(1–3):1–12. doi:10.1016/j.schres.2008.05.00918606526
   PubMed Web of Science ®Google Scholar
• Dibonaventura M, Gabriel S, Dupclay L, Gupta S, Kim E. A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia. BMC Psychiatry. 2012;12:20. doi:10.1186/1471-244X-12-2022433036
   PubMed Web of Science ®Google Scholar
• Godin O, Leboyer M, Schurhoff F, et al. Metabolic syndrome and illness severity predict relapse at 1-year follow-up in schizophrenia: the FACE-SZ cohort. J Clin Psychiatry. 2018;79:6. doi:10.4088/JCP.17m12007
   Web of Science ®Google Scholar
• Bora E, Akdede BB, Alptekin K. The relationship between cognitive impairment in schizophrenia and metabolic syndrome: a systematic review and meta-analysis. Psychol Med. 2017;47(6):1030–1040. doi:10.1017/S003329171600336628032535
   PubMed Web of Science ®Google Scholar
• Scigliano G, Ronchetti G. Antipsychotic-induced metabolic and cardiovascular side effects in schizophrenia: a novel mechanistic hypothesis. CNS Drugs. 2013;27(4):249–257. doi:10.1007/s40263-013-0054-123533011
   PubMed Web of Science ®Google Scholar
• Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry. 2003;160(2):284–289. doi:10.1176/appi.ajp.160.2.28412562574
   PubMed Web of Science ®Google Scholar
• Cordes J, Bechdolf A, Engelke C, et al. Prevalence of metabolic syndrome in female and male patients at risk of psychosis. Schizophr Res. 2017;181:38–42. doi:10.1016/j.schres.2016.09.01227751654
   PubMed Web of Science ®Google Scholar
• Ellingrod VL, Taylor SF, Dalack G, et al. Risk factors associated with metabolic syndrome in bipolar and schizophrenia subjects treated with antipsychotics: the role of folate pharmacogenetics. J Clin Psychopharmacol. 2012;32(2):261–265. doi:10.1097/JCP.0b013e318248588822370993
   PubMed Web of Science ®Google Scholar
• Cheng C, Chiu HJ, Loh E, et al. Association of the ADRA1A gene and the severity of metabolic abnormalities in patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2012;36(1):205–210. doi:10.1016/j.pnpbp.2011.10.01122037178
   PubMed Web of Science ®Google Scholar
• Henderson DC, Vincenzi B, Andrea NV, Ulloa M, Copeland PM. Pathophysiological mechanisms of increased cardiometabolic risk in people with schizophrenia and other severe mental illnesses. Lancet Psychiatry. 2015;2(5):452–464. doi:10.1016/S2215-0366(15)00115-726360288
   PubMed Web of Science ®Google Scholar
• Ventriglio A, Gentile A, Stella E, Bellomo A. Metabolic issues in patients affected by schizophrenia: clinical characteristics and medical management. Front Neurosci. 2015;9:297. doi:10.3389/fnins.2015.0029726388714
   PubMed Web of Science ®Google Scholar
• Tianmei S, Yan L. The risk of metabolic syndrome in patients with schizophrenia. J Psychiatry. 2009;22(1):66–69. doi:10.3969/j.issn.1009-7201.2009.01.028
   Google Scholar
• Khan AY, Zaidi DSN. Reducing morbidity and mortality from common medical conditions in schizophrenia. Curr Psychiatr. 2016;30–2(34–8):40.
   Google Scholar
• Stahl SM. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications (4th Edition). Cambridge: Cambridge University Press; 2013.
   Google Scholar
• Reynolds GP, Kirk SL. Metabolic side effects of antipsychotic drug treatment–pharmacological mechanisms. Pharmacol Ther. 2010;125(1):169–179. doi:10.1016/j.pharmthera.2009.10.01019931306
   PubMed Web of Science ®Google Scholar
• Aringhieri S, Carli M, Kolachalam S, et al. Molecular targets of atypical antipsychotics: from mechanism of action to clinical differences. Pharmacol Ther. 2018;192:20–41. doi:10.1016/j.pharmthera.2018.06.01229953902
   PubMed Web of Science ®Google Scholar
• Matsui-Sakata A, Ohtani H, Sawada Y. Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus. Drug Metab Pharmacokinet. 2005;20(5):368–378. doi:10.2133/dmpk.20.36816272755
   PubMedGoogle Scholar
• Montastruc F, Palmaro A, Bagheri H, Schmitt L, Montastruc JL, Lapeyre-Mestre M. Role of serotonin 5-HT2C and histamine H1 receptors in antipsychotic-induced diabetes: a pharmacoepidemiological-pharmacodynamic study in VigiBase. Eur Neuropsychopharmacol. 2015;25(10):1556–1565. doi:10.1016/j.euroneuro.2015.07.01026256010
   PubMed Web of Science ®Google Scholar
• Correll CU, Lencz T, Malhotra AK. Antipsychotic drugs and obesity. Trends Mol Med. 2011;17(2):97–107. doi:10.1016/j.molmed.2010.10.01021185230
   PubMed Web of Science ®Google Scholar
• Galletly C, Castle D, Dark F, et al. Royal Australian and New Zealand college of psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry. 2016;50(5):410–472. doi:10.1177/000486741664119527106681
   PubMed Web of Science ®Google Scholar
• Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia - a short version for primary care. Int J Psychiatry Clin Pract. 2017;21(2):82–90. doi:10.1080/13651501.2017.129183928498090
   PubMed Web of Science ®Google Scholar
• Jingping Z, Shenxun S. Guidelines for the Prevention and Treatment of Schizophrenia in China (Second Edition). Beijing: China Medical Electronic Audiovisual Publishing House; 2015.
   Google Scholar
• Dols A, Sienaert P, van Gerven H, et al. The prevalence and management of side effects of lithium and anticonvulsants as mood stabilizers in bipolar disorder from a clinical perspective: a review. Int Clin Psychopharmacol. 2013;28(6):287–296. doi:10.1097/YIC.0b013e32836435e223873292
   PubMed Web of Science ®Google Scholar
• Ng QX, Chong J, Chee KT. Add-on pharmacotherapy for patients with first-episode schizophrenia: a clinical perspective. Eur J Clin Pharmacol. 2020. doi:10.1007/s00228-020-02973-2
   Web of Science ®Google Scholar
• Delacretaz A, Vandenberghe F, Gholam-Rezaee M, et al. Early changes of blood lipid levels during psychotropic drug treatment as predictors of long-term lipid changes and of new onset dyslipidemia. J Clin Lipidol. 2018;12(1):219–229. doi:10.1016/j.jacl.2017.10.00229128242
   PubMed Web of Science ®Google Scholar
• Vandenberghe F, Najar-Giroud A, Holzer L, Conus P, Eap CB, Ambresin AE. Second-generation antipsychotics in adolescent psychiatric patients: metabolic effects and impact of an early weight change to predict longer term weight gain. J Child Adolesc Psychopharmacol. 2018;28(4):258–265. doi:10.1089/cap.2017.003829297696
   PubMed Web of Science ®Google Scholar
• Speyer H, Jakobsen AS, Westergaard C, et al. Lifestyle interventions for weight management in people with serious mental illness: a systematic review with meta-analysis, trial sequential analysis, and meta-regression analysis exploring the mediators and moderators of treatment effects. Psychother Psychosom. 2019;88(6):350–362. doi:10.1159/00050229331522170
   PubMed Web of Science ®Google Scholar
• Speyer H, Christian BNH, Birk M, et al. The CHANGE trial: no superiority of lifestyle coaching plus care coordination plus treatment as usual compared to treatment as usual alone in reducing risk of cardiovascular disease in adults with schizophrenia spectrum disorders and abdominal obesity. World Psychiatry. 2016;15(2):155–165. doi:10.1002/wps.2031827265706
   PubMed Web of Science ®Google Scholar
• Curtis J, Watkins A, Rosenbaum S, et al. Evaluating an individualized lifestyle and life skills intervention to prevent antipsychotic-induced weight gain in first-episode psychosis. Early Interv Psychiatry. 2016;10(3):267–276. doi:10.1111/eip.1223025721464
   PubMed Web of Science ®Google Scholar
• Firth J, Marx W, Dash S, et al. The effects of dietary improvement on symptoms of depression and anxiety: a meta-analysis of randomized controlled trials. Psychosom Med. 2019;81(3):265–280. doi:10.1097/PSY.000000000000067330720698
   PubMed Web of Science ®Google Scholar
• Marteene W, Winckel K, Hollingworth S, et al. Strategies to counter antipsychotic-associated weight gain in patients with schizophrenia. Expert Opin Drug Saf. 2019;18(12):1149–1160. doi:10.1080/14740338.2019.167480931564170
   PubMed Web of Science ®Google Scholar
• Mizuno Y, Suzuki T, Nakagawa A, et al. Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. Schizophr Bull. 2014;40(6):1385–1403. doi:10.1093/schbul/sbu03024636967
   PubMed Web of Science ®Google Scholar
• Wu RR, Zhao JP, Jin H, et al. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA. 2008;299(2):185–193. doi:10.1001/jama.2007.56-b18182600
   PubMed Web of Science ®Google Scholar
• Fan X, Borba CP, Copeland P, et al. Metabolic effects of adjunctive aripiprazole in clozapine-treated patients with schizophrenia. Acta Psychiatr Scand. 2013;127(3):217–226. doi:10.1111/acps.1200922943577
   PubMed Web of Science ®Google Scholar
• Deberdt W, Winokur A, Cavazzoni PA, et al. Amantadine for weight gain associated with olanzapine treatment. Eur Neuropsychopharmacol. 2005;15(1):13–21. doi:10.1016/j.euroneuro.2004.03.00515572269
   PubMed Web of Science ®Google Scholar
• Ko YH, Joe SH, Jung IK, Kim SH. Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain. Clin Neuropharmacol. 2005;28(4):169–175. doi:10.1097/01.wnf.0000172994.56028.c316062095
   PubMed Web of Science ®Google Scholar
• Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ. 2007;335(7631):1194–1199. doi:10.1136/bmj.39385.413113.2518006966
   PubMed Web of Science ®Google Scholar
• Romo-Nava F, Alvarez-Icaza GD, Fresan-Orellana A, et al. Melatonin attenuates antipsychotic metabolic effects: an eight-week randomized, double-blind, parallel-group, placebo-controlled clinical trial. Bipolar Disord. 2014;16(4):410–421. doi:10.1111/bdi.1219624636483
   PubMed Web of Science ®Google Scholar
• Poyurovsky M, Fuchs C, Pashinian A, et al. Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. Psychopharmacology (Berl). 2007;192(3):441–448. doi:10.1007/s00213-007-0731-117310385
   PubMed Web of Science ®Google Scholar
• Ghanizadeh A, Nikseresht MS, Sahraian A. The effect of zonisamide on antipsychotic-associated weight gain in patients with schizophrenia: a randomized, double-blind, placebo-controlled clinical trial. Schizophr Res. 2013;147(1):110–115. doi:10.1016/j.schres.2013.03.02123583010
   PubMed Web of Science ®Google Scholar
• Jarskog LF, Hamer RM, Catellier DJ, et al. Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. Am J Psychiatry. 2013;170(9):1032–1040. doi:10.1176/appi.ajp.2013.1201012723846733
   PubMed Web of Science ®Google Scholar
• Wu RR, Jin H, Gao K, et al. Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia: a double-blind, randomized, placebo-controlled study. Am J Psychiatry. 2012;169(8):813–821. doi:10.1176/appi.ajp.2012.1109143222711171
   PubMed Web of Science ®Google Scholar
• Carrizo E, Fernandez V, Connell L, et al. Extended release metformin for metabolic control assistance during prolonged clozapine administration: a 14 week, double-blind, parallel group, placebo-controlled study. Schizophr Res. 2009;113(1):19–26. doi:10.1016/j.schres.2009.05.00719515536
   PubMed Web of Science ®Google Scholar
• Klein DJ, Cottingham EM, Sorter M, Barton BA, Morrison JA. A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry. 2006;163(12):2072–2079. doi:10.1176/ajp.2006.163.12.207217151157
   PubMed Web of Science ®Google Scholar
• Bouchoucha M, Uzzan B, Cohen R. Metformin and digestive disorders. Diabetes Metab. 2011;37(2):90–96. doi:10.1016/j.diabet.2010.11.00221236717
   PubMed Web of Science ®Google Scholar
• Keks N, Schwartz D, Hope J. Stopping and switching antipsychotic drugs. Aust Prescr. 2019;42(5):152–157. doi:10.18773/austprescr.2019.05231631928
   PubMed Web of Science ®Google Scholar
• Lin CC, Bai YM, Wang YC, et al. Improved body weight and metabolic outcomes in overweight or obese psychiatric patients switched to amisulpride from other atypical antipsychotics. J Clin Psychopharmacol. 2009;29(6):529–536. doi:10.1097/JCP.0b013e3181bf613e19910716
   PubMed Web of Science ®Google Scholar
• Kim Y, Wang SM, Kwak KP, et al. Amisulpride switching in schizophrenic patients who showed suboptimal effect and/or tolerability to current antipsychotics in a naturalistic setting: an Explorative Study. Clin Psychopharmacol Neurosci. 2016;14(4):371–377. doi:10.9758/cpn.2016.14.4.37127776390
   PubMed Web of Science ®Google Scholar
• Linden M, Eich FX, Pyrkosch L. Do differences in atypical antipsychotics matter in routine practice? Medication switch from olanzapine and risperidone to amisulpride. Int Clin Psychopharmacol. 2007;22(3):175–178. doi:10.1097/YIC.0b013e3280148c1917414744
   PubMed Web of Science ®Google Scholar
• Linden M, Scheel T, Eich FX. Improvement of patient compliance after switching from conventional neuroleptics to the atypical neuroleptic amisulpride. J Psychopharmacol. 2006;20(6):815–823. doi:10.1177/026988110606115416401647
   PubMed Web of Science ®Google Scholar
• Stroup TS, McEvoy JP, Ring KD, et al. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry. 2011;168(9):947–956. doi:10.1176/appi.ajp.2011.1011160921768610
   PubMed Web of Science ®Google Scholar
• Newcomer JW, Campos JA, Marcus RN, et al. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. J Clin Psychiatry. 2008;69(7):1046–1056. doi:10.4088/jcp.v69n070218605811
   PubMed Web of Science ®Google Scholar
• Wani RA, Dar MA, Chandel RK, et al. Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study. Neuropsychiatr Dis Treat. 2015;11:685–693. doi:10.2147/NDT.S8092525792838
   PubMed Web of Science ®Google Scholar
• Casey DE, Carson WH, Saha AR, et al. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl). 2003;166(4):391–399. doi:10.1007/s00213-002-1344-312610718
   PubMed Web of Science ®Google Scholar
• Kim SW, Shin IS, Kim JM, et al. Effectiveness of switching to aripiprazole from atypical antipsychotics in patients with schizophrenia. Clin Neuropharmacol. 2009;32(5):243–249. doi:10.1097/WNF.0b013e31819a68b519620849
   PubMed Web of Science ®Google Scholar
• Chen Y, Bobo WV, Watts K, Jayathilake K, Tang T, Meltzer HY. Comparative effectiveness of switching antipsychotic drug treatment to aripiprazole or ziprasidone for improving metabolic profile and atherogenic dyslipidemia: a 12-month, prospective, open-label study. J Psychopharmacol. 2012;26(9):1201–1210. doi:10.1177/026988111143074822234928
   PubMed Web of Science ®Google Scholar
• Mattingly GW, Haddad PM, Tocco M, et al. Switching to lurasidone following 12 months of treatment with risperidone: results of a 6-month, open-label study. BMC Psychiatry. 2020;20(1):199. doi:10.1186/s12888-020-02523-132370778
   PubMed Web of Science ®Google Scholar
• Deberdt W, Lipkovich I, Heinloth AN, et al. Double-blind, randomized trial comparing efficacy and safety of continuing olanzapine versus switching to quetiapine in overweight or obese patients with schizophrenia or schizoaffective disorder. Ther Clin Risk Manag. 2008;4(4):713–720. doi:10.2147/tcrm.s315319209252
   PubMedGoogle Scholar
• Weiden PJ, Newcomer JW, Loebel AD, Yang R, Lebovitz HE. Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone. Neuropsychopharmacol. 2008;33(5):985–994. doi:10.1038/sj.npp.1301482
   PubMed Web of Science ®Google Scholar
• Wang HH, Cai M, Wang HN, et al. An assessor-blinded, randomized comparison of efficacy and tolerability of switching from olanzapine to ziprasidone and the combination of both in schizophrenia spectrum disorders. J Psychiatr Res. 2017;85:59–65. doi:10.1016/j.jpsychires.2016.11.00227837658
   PubMed Web of Science ®Google Scholar
• Alptekin K, Hafez J, Brook S, et al. Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study. Int Clin Psychopharmacol. 2009;24(5):229–238. doi:10.1097/YIC.0b013e32832c262419531959
   PubMed Web of Science ®Google Scholar
• Li CH, Shi L, Zhan GL, Rao SZ, Zhang H. A twenty-four-week, open-label study on ziprasidone’s efficacy and influence on glucolipid metabolism in patients with schizophrenia and metabolic disorder. Eur Rev Med Pharmacol Sci. 2013;17(16):2136–2140.23893178
   PubMed Web of Science ®Google Scholar
• Ishigooka J, Usami T, Iwashita S, Kojima Y, Matsuo S. Post-hoc analysis investigating the safety and efficacy of brexpiprazole in Japanese patients with schizophrenia who were switched from other antipsychotics in a long-term study (secondary publication). Neuropsychopharmacol Rep. 2020;40(2):122–129. doi:10.1002/npr2.1210732297486
   PubMed Web of Science ®Google Scholar
• Correll CU, Shi L, Weiss C, et al. Successful switching of patients with acute schizophrenia from another antipsychotic to brexpiprazole: comparison of clinicians’ choice of cross-titration schedules in a post hoc analysis of a randomized, double-blind, maintenance treatment study. CNS Spectr. 2019;24(5):507–517. doi:10.1017/S109285291800108630306884
   PubMed Web of Science ®Google Scholar
• Burns T, Chabannes JP, Demyttenaere K. Switching antipsychotic medications: general recommendations and switching to amisulpride. Curr Med Res Opin. 2002;18(4):201–208. doi:10.1185/03007990212500058912201620
   PubMed Web of Science ®Google Scholar
• Weber M, Gutierrez AM, Mohammadi M. The risks and benefits of switching antipsychotics: a case study approach. Perspect Psychiatr Care. 2009;45(1):54–61. doi:10.1111/j.1744-6163.2009.00200.x19154240
   PubMed Web of Science ®Google Scholar
• Pae CU, Serretti A, Chiesa A, et al. Immediate versus gradual suspension of previous treatments during switch to aripiprazole: results of a randomized, open label study. Eur Neuropsychopharmacol. 2009;19(8):562–570. doi:10.1016/j.euroneuro.2009.04.00219442491
   PubMed Web of Science ®Google Scholar
• Correll CU, Sikich L, Reeves G, et al. Metformin add-on vs. antipsychotic switch vs. continued antipsychotic treatment plus healthy lifestyle education in overweight or obese youth with severe mental illness: results from the IMPACT trial. World Psychiatry. 2020;19(1):69–80. doi:10.1002/wps.2071431922663
   PubMed Web of Science ®Google Scholar
• Josiassen RC, Joseph A, Kohegyi E, et al. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2005;162(1):130–136. doi:10.1176/appi.ajp.162.1.13015625211
   PubMed Web of Science ®Google Scholar
• Sacks D, Baxter B, Campbell B, et al. Multisociety consensus quality improvement revised consensus statement for endovascular therapy of acute ischemic stroke. Int J Stroke. 2018;13(6):612–632. doi:10.1177/174749301877871329786478
   PubMed Web of Science ®Google Scholar
• Sanghani SN, Petrides G, Kellner CH. Electroconvulsive therapy (ECT) in schizophrenia: a review of recent literature. Curr Opin Psychiatry. 2018;31(3):213–222. doi:10.1097/YCO.000000000000041829528902
   PubMed Web of Science ®Google Scholar